Clark v. Lovelace Health Systems, Inc.

2004 NMCA 119, 99 P.3d 232, 136 N.M. 411
CourtNew Mexico Court of Appeals
DecidedAugust 27, 2004
Docket23,829
StatusPublished
Cited by15 cases

This text of 2004 NMCA 119 (Clark v. Lovelace Health Systems, Inc.) is published on Counsel Stack Legal Research, covering New Mexico Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Clark v. Lovelace Health Systems, Inc., 2004 NMCA 119, 99 P.3d 232, 136 N.M. 411 (N.M. Ct. App. 2004).

Opinion

OPINION

ALARID, Judge.

{1} Plaintiffs appeal the dismissal of their civil complaint brought on behalf of Decedent for medical malpractice, wrongful death, and strict products liability. Below, Defendants moved to dismiss the complaint because it was filed after the three-year statute of limitations had run under NMSA 1978, § 41-2-2 (1961) (Wrongful Death statute). Plaintiffs argued below that a discovery rule should apply to the statute of limitations under the Wrongful Death Statute. The trial court disagreed and dismissed the complaint without prejudice. We affirm for the reasons discussed in this opinion.

BACKGROUND

{2} Some time prior to his death, Decedent was diagnosed with severe obstructive sleep apnea and it had been recommended that he not use sedative medications. On April 8, 1998, Dr. Pereira, with the recommendation of Dr. Brasher, prescribed methadone for Decedent’s pain, despite its potential for causing drowsiness. That same day, Decedent began to take the methadone. Decedent died on April 10,1998, and an autopsy was performed. Dr. Yousef, who performed the autopsy, concluded that he died of methadone intoxication. The medication log taken at the time of death indicated that Decedent was taking methadone, along with Amitriptyline, PCN, Promethazine, Propulsid, Zantac, and Zyrtec. The autopsy revealed methadone, antidepressants and sleep medication in Decedent’s system.

{3} On March 23, 2000, the FDA announced that marketing of Propulsid would be discontinued on July 14, 2000, due to its association with 341 reports of heart rhythm abnormalities and 80 reports of deaths, as of December 31, 1999. Plaintiffs filed their initial complaint on August 31, 2000. On May 9, 2001, just over three years after Decedent’s death, Dr. Brasher was deposed. Dr. Brasher testified that it appeared that Decedent had taken twice the recommended dose of prescribed methadone over the two days before his death. He testified that he did not know what killed Decedent, but that, in his opinion, Propulsid would be “at the top of the list” if he were autopsied today. Dr. Brasher testified that it would not have been known on the date of Decedent’s death, in 1998, that Propulsid would have ranked high as a suspect. Dr. Brasher further noted that there was a possibility of interactions with other medications taken by Decedent, but concluded that, if the autopsy was performed “today,” Propulsid “would be blamed if no other obvious explanation was present.” Based on this information, Plaintiffs were allowed to amend their complaint to add Defendants Johnson & Johnson (J & J), and Janssen Pharmaceutica Inc. (Janssen) relative to their products liability claim and concerning the drug Propulsid.

{4} The amended complaint was filed on March 22, 2002. Defendants successfully moved to dismiss the amended complaint as to J & J and Janssen based on the fact that it was filed over three years after Decedent died.

{5} Plaintiffs appeal the trial court’s decision. According to Plaintiffs, the issue on appeal is whether the specific language in the Wrongful Death statute, stating that a cause of action accrues as of the date of death, “prevents the application of the discovery rule in the case of death.”

DISCUSSION

Standard of Review

{6} Defendants filed a motion to dismiss the amended complaint under Rule 1-012(B)(6) NMRA 2004. Plaintiffs responded, arguing that a discovery rule should apply to the statute of limitations under the Wrongful Death statute. Following a hearing on the motion, the amended complaint was dismissed. Plaintiffs contend that the order of dismissal should be viewed as an order granting summary judgment because the trial court considered matters outside the pleadings. It appears that Plaintiffs are referring to the documents attached to then-response to Defendants’ motion to dismiss, which included an affidavit, portions of the deposition of Dr. Brasher, the autopsy report, the list of medications used by Decedent, and an article announcing the position of the FDA with respect to the withdrawal of Propulsid from the market. Defendants argue that the trial court “must not have considered matters outside the pleadings” for several reasons. Defendants point out that the trial court was presented with a Rule 12-012(B)(6) motion to dismiss and entered an order titled, “Order Granting Johnson & Johnson, Inc. and Janssen Pharmaeeutica Inc.’s Rule 1-012(B)(6) Motion to Dismiss Plaintiffs’ First Amended Complaint.” Defendants, citing a federal ease, also argue that the affidavit attached to the response cannot be considered under a Rule 1-012(B)(6) standard, and the attachments to the response could not change the motion to a motion for summary judgment because Defendants restricted their argument at the hearing to the allegations in the complaint and did not rely on the information contained in the attachments. See Dunn v. McFeeley, 1999-NMCA-084, ¶¶ 10-11, 127 N.M. 513, 984 P.2d 760 (determining that, although the literal language of the rule states that a motion to dismiss is converted to a motion for summary judgment if matters outside the pleadings are presented to and not excluded by the trial court, where the parties restricted their argument to the allegations of the amended complaint and did not purport to rely on attachments, and the trial court and the parties treated the motion as simply a motion to dismiss, appellate court will not decide the case on grounds not relied on by the trial court but will treat the motion as a motion to dismiss).

{7} Based on the transcript of the hearing, the parties did not rely on the factual information in the attachments to Plaintiffs’ response when making their arguments to the trial court. Instead, the parties presented only legal argument regarding interpretation of the Wrongful Death statute. The trial court also did not consider the facts included in the attachments when making its decision on Defendants’ motion. In fact, during the hearing, when Plaintiffs’ attorney stated that he had included in the response “some of the facts about the knowledge that was apparent to the Plaintiffs at the time that they filed the case and as they proceeded,” the trial court responded, “I don’t have any problem with the facts,” and then asked a question concerning the legal arguments that had been made. The trial court made a legal determination that “the legislature has tinkered” with the Wrongful Death statute a number of times and, if the legislature felt it necessary to change the act, it would have done so. The trial court determined that the legislature had been “fairly clear about it,” and dismissed the case based on existing case law. In other words, the trial court treated the motion only as a motion to dismiss. Plaintiffs did not protest the trial court’s actions, did not argue that the motion had been converted to a summary judgment motion, and did not make an offer of proof or preserve any argument regarding the factual information included in the attachments. The trial court did not review the motion as a summary judgment motion, and we will not do so either.

{8} We review, de novo, a motion to dismiss under Rule 1-012(B)(6), accepting as true all of the well-pleaded facts alleged in the complaint, and “resolving all doubts in favor of the sufficiency of the complaint.” See Envtl. Control, Inc. v. City of Santa Fe, 2002-NMCA-003, ¶ 6, 131 N.M. 450, 38 P.3d 891.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State v. Montano
New Mexico Court of Appeals, 2022
State v. Vest
428 P.3d 287 (New Mexico Court of Appeals, 2018)
Estate of Brice Ex Rel. Tracy A. v. Toyota Motor Corp.
2016 NMSC 018 (New Mexico Supreme Court, 2016)
State v. Chavez
2016 NMCA 016 (New Mexico Court of Appeals, 2015)
Warner v. Calvert
2011 NMCA 028 (New Mexico Court of Appeals, 2011)
Kinder Morgan CO2 Co. v. State Taxation & Revenue Department
2009 NMCA 019 (New Mexico Court of Appeals, 2008)
State v. GROSSETETE
2008 NMCA 088 (New Mexico Court of Appeals, 2008)
Celnik v. Congregation B'Nai Israel
2006 NMCA 039 (New Mexico Court of Appeals, 2006)
State Farm Mutual Auto. Ins. Co. v. Luebbers
119 P.3d 169 (New Mexico Court of Appeals, 2005)
State Farm Mutual Automobile Insurance v. Luebbers ex rel. Salazar
2005 NMCA 112 (New Mexico Court of Appeals, 2005)
O'Sullivan v. Rhode Island Hospital
874 A.2d 179 (Supreme Court of Rhode Island, 2005)
Maestas v. Zager
2005 NMCA 013 (New Mexico Court of Appeals, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
2004 NMCA 119, 99 P.3d 232, 136 N.M. 411, Counsel Stack Legal Research, https://law.counselstack.com/opinion/clark-v-lovelace-health-systems-inc-nmctapp-2004.